文献类型：期刊文献

英文题名：Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review

作者：Li, Yaoqi[1];Wang, You[2];Shen, Rui[3];Liu, Weijun[4];Zhu, Chenglou[1,5]

第一作者：Li, Yaoqi

通信作者：Zhu, CL[1];Zhu, CL[2]

机构：[1]Gansu Prov Hosp, Dept Surg Oncol, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Sch Clin Med 1, Lanzhou, Peoples R China;[3]Chengxian Peoples Hosp, Dept Gen Surg, Chengxian, Peoples R China;[4]Longxi Cty First Peoples Hosp, Dept Gen Surg, Longxi, Peoples R China;[5]Lanzhou Univ, Sch Clin Med 1, Lanzhou, Peoples R China

第一机构：Gansu Prov Hosp, Dept Surg Oncol, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Gansu Prov Hosp, Dept Surg Oncol, Lanzhou, Peoples R China;[2]corresponding author), Lanzhou Univ, Sch Clin Med 1, Lanzhou, Peoples R China.

年份：2025

卷号：15

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105009342696);WOS:【SCI-EXPANDED(收录号:WOS:001516424500001)】；

基金：The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Natural Science Foundation of Gansu Province (grant number 25JRRA871 23JRRA1317).

语种：英文

外文关键词：gastric cancer; HPD; sintilimab; risk factors; mechanisms

摘要：Objective To investigate the risk factors, underlying mechanisms, and preventive strategies associated with hyperprogressive disease (HPD) induced by immunotherapy.Methods We analyzed the clinical data of a patient who developed HPD following palliative gastrectomy and received a combination therapy of Sintilimab, S-1 (tegafur, gimeracil, and oteracil potassium), and Oxaliplatin (SOX). Additionally, a literature review on tumor immunotherapy was conducted to further explore the risk factors and mechanisms of HPD.Results In this case, the development of HPD was associated with a high postoperative tumor burden, elevated PD-1 expression, and aberrant activation of signaling pathways mediated by EGFR, MET, and FGFR1 amplifications. In addition, a TP53 p.F270V mutation led to inactivation of tumor suppressor function.Conclusion Although immune checkpoint inhibitors (ICIs) have demonstrated significant efficacy in cancer treatment, HPD induced by ICIs can drastically shorten patients' OS, warranting cautious use in populations with high-risk factors. Effective prevention of HPD involves screening for risk factors, monitoring predictive biomarkers such as circulating-free DNA (cfDNA) via liquid biopsy, and identifying high-risk populations through gene mutation analysis.